Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers.

Gounder MM, Martin-Romano P, Italiano A, Siu LL, Cassier PA, Falchook GS, Lossos IS, Rasco DW, Hilton JF, McKean MA, Opdam FL, Strauss J, De Jonge M, Vermaat JSP, Crossman T, Zajac M, Tarkar A, Gonzalez Carreras F, Kremer BE, Barbash O, Segal S, Parasrampuria R, Postel-Vinay S

Open source

DOI: 10.1016/j.annonc.2025.08.3757
Published: 2025 Dec
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2025.08.3757,
  title = {Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers.},
  author = {Gounder MM and Martin-Romano P and Italiano A and Siu LL and Cassier PA and Falchook GS and Lossos IS and Rasco DW and Hilton JF and McKean MA and Opdam FL and Strauss J and De Jonge M and Vermaat JSP and Crossman T and Zajac M and Tarkar A and Gonzalez Carreras F and Kremer BE and Barbash O and Segal S and Parasrampuria R and Postel-Vinay S},
  year = {2025},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2025.08.3757},
  url = {https://doi.org/10.1016/j.annonc.2025.08.3757}
}

RIS

TY  - JOUR
TI  - Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers.
AU  - Gounder MM
AU  - Martin-Romano P
AU  - Italiano A
AU  - Siu LL
AU  - Cassier PA
AU  - Falchook GS
AU  - Lossos IS
AU  - Rasco DW
AU  - Hilton JF
AU  - McKean MA
AU  - Opdam FL
AU  - Strauss J
AU  - De Jonge M
AU  - Vermaat JSP
AU  - Crossman T
AU  - Zajac M
AU  - Tarkar A
AU  - Gonzalez Carreras F
AU  - Kremer BE
AU  - Barbash O
AU  - Segal S
AU  - Parasrampuria R
AU  - Postel-Vinay S
PY  - 2025
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2025.08.3757
UR  - https://doi.org/10.1016/j.annonc.2025.08.3757
ER  -

APA

MM, G., P, M., A, I., LL, S., PA, C., GS, F., IS, L., DW, R., JF, H., MA, M., FL, O., J, S., M, D. J., JSP, V., T, C., M, Z., A, T., F, G. C., BE, K., O, B., S, S., R, P., & S, P. (2025). Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2025.08.3757

Source records

pubmed · retrieved 2026-09-26T02:24:49.045Z